Table 1
Findings Suspicious of FH
Age Untreated Fasting Cholesterol Concentrations Physical Manifestations*
< 20 years
  • LDL-C: ≥ 160mg/dL
  • Non-HDL: ≥ 190mg/dL
  • Tendon xanthomas
  • Arcus cornea
  • Xanthelasma
≥ 20 years
  • LDL-C: ≥ 190mg/dL
  • Non-HDL: ≥ 220mg/dL
  • Tendon xanthomas
  • Arcus cornea (in patients > 45 years)
*Absence of these manifestations should not be used to exclude diagnosis.
Patel et al. Pharmacotherapy. 2015. Dec;35(12):1189-203.1
Table 2
Tools for Formally Diagnosing FH
  • US Make Early Diagnoses Prevent Early Deaths Program Diagnostic (MEDPED) Criteria
  • The Dutch Lipid Clinic Network
  • Simon Broome Registry
Hopkins et al. J Clin Lipidol. 2011 Jun;5(3 Suppl):S9-17.2

Table 3
FH Patients at Highest Risk of CVD
  • Established CVD
  • Diabetes mellitus
  • Family history of premature CHD
  • Smokers
  • Two or more of the following risk factors
    • Men > 30 years
    • Women > 40 years
    • Baseline LDL-C > 250 mg/dL
    • Male sex
    • Current smoker
    • Premature on set of CHD in first-degree man >55 years or first-degree women < 65 years
    • Metabolic syndrome
    • HDL-C < 40 mg/dL
    • Hypertension
    • Lipoprotein(a) ≥ 50 mg/dL
    • Tendon xanthoma
Patel et al. Pharmacotherapy. 2015. Dec;35(12):1189-203.1

Continue Reading


1. Patel RS, Scopelliti EM, Savelloni J. Therapeutic management of familial hypercholesterolemia: current and emerging drug therapies. Pharmacotherapy. 2015. Dec;35(12):1189-203.

2. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol.  2011 Jun;5(3 Suppl):S9-17.

3. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general  population: guidance for clinicians to prevent coronary heart disease: consensus  statement of the European Atherosclerosis Society. Eur Heart J. 2013 Dec;34(45):3478-90a.

4. Alonso R, Mata N, Castillo S, et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis. 2008 Oct;200(2):315-21.

5. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol. 2008 Dec 1;102(11):1438-43.

6. National Collaborating Centre for Primary Care (UK). Identification and Management of Familial Hypercholesterolaemia (FH) [Internet]. London: Royal College of General Practitioners (UK); 2008 Aug. (NICE Clinical Guidelines, No. 71.) Available from:

7. Vogt A. The genetics of familial hypercholesterolemia and emerging therapies. Appl Clin Genet. 2015 Jan 28;8:27-36.

8. Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, Chin W, Tribble DL, McGowan M. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012 Nov 6;126(19):2283-92.